2. Cytoskeleton Autophagy Apoptosis Stem Cell/Wnt JAK/STAT Signaling Immunology/Inflammation
  3. Integrin Autophagy Apoptosis STAT PD-1/PD-L1
  4. Cilengitide

Cilengitide  (Synonyms: 西仑吉肽; EMD 121974)

目录号: HY-16141 纯度: 99.80%
Data Sheet SDS COA 产品使用指南 技术支持

溶解度

动物溶解方案

实验小贴士

Cilengitide (EMD 121974) 是一种强效的整合素拮抗剂，IC50 分别为 0.61 nM (ανβ3)，8.4 nM (ανβ5) 和 14.9 nM (α5β1)。Cilengitide 抑制 ανβ3 和 ανβ5 与玻连蛋白结合，IC50 值分别为 4 和 79 nM。Cilengitide 能够抑制 TGF-β/Smad 信号通路，调节 PD-L1 表达。Cilengitide 诱导凋亡 (apoptosis)，在对胶质母细胞瘤和其他癌症的研究中也显示出抗血管生成的作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cilengitide Chemical Structure

Cilengitide Chemical Structure

CAS No. : 188968-51-6

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1580
In-stock
1 mg ￥491
In-stock
5 mg ￥1220
In-stock
10 mg ￥1730
In-stock
25 mg ￥2980
In-stock
50 mg ￥4488
In-stock
100 mg 现货 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cilengitide:

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 46 篇科研文献

Proliferation Assay
IF
WB
IHC

    Cilengitide purchased from MCE. Usage Cited in: Cell Adh Migr. 2019 Jan 21:1-12.   [Abstract]

    HepG2 cells are loaded with FSS at 1 dyn/cm2 for 0.5 h, with or without treatment of 0.5 μM Cli for 6 h prior to FSS application. Lysates are probed with antibodies as indicated.

    Cilengitide purchased from MCE. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352.  [Abstract]

    Representative Western blot images of ανβ5 and collagen I protein expression in WKY- and SHR-CF cultured on substrates with two different stiffness (high and low) and contemporary treated with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide.

    Cilengitide purchased from MCE. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352.  [Abstract]

    Representative images of immunofluorescence performed for α-SMA on WKY- and SHR-CF in the treatment of TGF-β1, cilengitide or both.

    Cilengitide purchased from MCE. Usage Cited in: Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427.  [Abstract]

    C2C12 cells are pre-incubated with different concentrations of Cilengitide prior to LPA 20 μg/mL addition and incubation for 3 hours. CTGF levels are analyzed.

    Cilengitide purchased from MCE. Usage Cited in: PLoS One. 2016 Feb 3;11(2):e0148333.  [Abstract]

    Blockade of cellular adhesion of HEK 293 cells at 10 or 30 nM coated recombinant OPN forms with 1μM antagonistic integrin inhibitors. RGES (black bars) is used as a control peptide. Cilengitide (white bars) inhibits the integrins αVβ3, αVβ5, and α5β1. TR-14035 (hatched bars) inhibits the integrins α4β7 and α4β1. Depicted are the means ± SEM of 3 independent experiments. * indicate signif

    Cilengitide purchased from MCE. Usage Cited in: Department of Bioengineering. Santa Clara University. Jun 12, 2014 .

    Cilengitide Photos: Pictures of migration through alginate with and without Cilengitide after four days. A) The view of the bottom of the untreated well, showing a healthy monolayer of U87s. B) The view of the cells suspended in alginate in the untreated well. A few of the multiple migrated cells within the image are marked with arrows. C) The view of the bottom of the Cilengitide treated well, showing very few, ill-attached U87s. D). The view of cells suspended in alginate in the Cilengitide-tr

    查看 Integrin 亚型特异性产品:

    查看所有亚型
    αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

    查看 STAT 亚型特异性产品:

    查看所有亚型
    STAT3 STAT5 STAT6 STAT1

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers[1][2][3].

    IC50 & Target[1][2][3]

    αvβ3

    4 nM (IC50, αvβ3-Vitronectin interaction[2])

    αvβ5

    79 nM (IC50, αvβ5-Vitronectin interaction[2])

    αvβ3

    0.61 nM (IC50, [1])

    αvβ5

    8.4 nM (IC50, [1])

    α5β1

    14.9 nM (IC50, [1])

    STAT3

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    CHO IC50
    0.54 nM
    Compound: Cilengitide
    Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay
    Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay
    		[PMID: 32094009]
    CHO IC50
    15.4 nM
    Compound: Cilengitide
    Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay
    Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay
    		[PMID: 32094009]
    CHO IC50
    8 nM
    Compound: Cilengitide
    Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay
    Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay
    		[PMID: 32094009]
    HEK-293T IC50
    0.51 nM
    Compound: c(RGDfV)
    Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay
    Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay
    		[PMID: 24095096]
    M21 IC50
    0.4 nM
    Compound: c[RGDf(Me)V]; Cilengitide
    Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2
    Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2
    		[PMID: 26753814]
    体外研究
    (In Vitro)

    Cilengitide is a cyclized RGD (Arg-Gly-Asp motif)-containing pentapeptide. Cilengitide blocks integrin ανβ3- and ανβ5-mediated endothelial cell attachment and migration[2].
    Cilengitide inhibits integrin-mediated binding to Vitronectin with IC50s of 0.4 and 0.4 μM in cell adhesion studies assessing the human melanoma M21 or UCLA-P3 human lung carcinoma cell lines[2].
    Cilengitide inhibits the attachment of human umbilical vein endothelial cells to Vitronectin with an IC50 of 2 μM[2].
    Cilengitide (0-1 mg/mL; 24-72 h) inhibits cell viability of melanoma cells in vitro and (5 μg/mL; 12 h) induces B16 and A375 cells apoptosis[3].
    Cilengitide (5 μg/mL, 10 μg/mL; 2 weeks) inhibits colony formation of B16 and A375 cells[3].
    Cilengitide (0-20 μg/mL; 12 h) inhibits STAT3 phosphorylation to decrease the expression of PD-L1[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[3]

    Cell Line: B16 and A375 cells
    Concentration: 0, 5, 10, and 20 μg/mL
    Incubation Time: 12 hours
    Result: Suppressed PD-L1 expression and STAT3 phosphorylation at concentrations greater than 5 µg/mL.

    Apoptosis Analysis[3]

    Cell Line: B16 and A375 cells
    Concentration: 5 μg/mL
    Incubation Time: 12 hours
    Result: Resulted apoptosis rates in B16 and A375 cells of 15.27% and 14.89%, respectively.
    体内研究
    (In Vivo)

    Cilengitide (i.p. at 10, 50, and 250 μg three times per week) inhibits M21-L melanoma tumors growth in nude mice[2].
    Cilengitide (50 mg/kg; i.p.; daily) enhances the function of CD8+ T cells and promotes anti-PD1 efficacy with Anti-PD1 monoclonal antibody in B16 murine melanoma model[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice bearing M21-L melanoma tumors[2]
    Dosage: 10, 50, and 250 μg
    Administration: Dosed i.p. three times per week
    Result: Demonstrated inhibition of tumor growth with a reduction in both tumor volume (55%, 75%, and 89%, respectively) and tumor weight (23%, 38%, and 61%, respectively), when compared to controls.
    Animal Model: Female C57BL/6 mice (6-8 weeks old) with B16 cells s.c.[3]
    Dosage: 50 mg/kg; with or without 10 mg/kg Anti-PD1 monoclonal antibody or isotype control i.p. every 3 days;
    Administration: Intraperitoneal injection; daily
    Result: Downregulated the expression of PD-L1 via STAT3 pathway and decreased the expression of PD-L1.
    Clinical Trial
    NCT NumberSponsorConditionStart DatePhase
    NCT00121238National Cancer Institute (NCI)
    Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer
    		January 2005Phase 2
    NCT00006222National Cancer Institute (NCI)
    Sarcoma
    		September 2000Phase 1
    NCT00112866National Cancer Institute (NCI)
    Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor
    		January 2005Phase 2
    分子量

    588.66

    Formula

    C27H40N8O7
    CAS 号
    性状

    固体

    颜色

    White to light yellow

    中文名称

    西仑吉肽
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : ≥ 44 mg/mL (74.75 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    H2O 中的溶解度 : 40 mg/mL (67.95 mM; adjust pH to 1 with 1 M HCL)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.6988 mL 8.4939 mL 16.9877 mL
    5 mM 0.3398 mL 1.6988 mL 3.3975 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    * 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比； 如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂： PBS

      Solubility: 100 mg/mL (169.88 mM); 澄清溶液; 超声助溶

    扫码获得
    动物溶解方案

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    纯度 & 产品资料

    纯度： 99.80%

    Data Sheet (634 KB) SDS (393 KB)

    COA (291 KB)HNMR (142 KB)RP-HPLC (255 KB)LCMS (235 KB)元素分析报告 (215 KB)

    产品使用指南 (1538 KB)
    参考文献

    Cilengitide 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.6988 mL 8.4939 mL 16.9877 mL 42.4693 mL
    5 mM 0.3398 mL 1.6988 mL 3.3975 mL 8.4939 mL
    10 mM 0.1699 mL 0.8494 mL 1.6988 mL 4.2469 mL
    15 mM 0.1133 mL 0.5663 mL 1.1325 mL 2.8313 mL
    20 mM 0.0849 mL 0.4247 mL 0.8494 mL 2.1235 mL
    25 mM 0.0680 mL 0.3398 mL 0.6795 mL 1.6988 mL
    30 mM 0.0566 mL 0.2831 mL 0.5663 mL 1.4156 mL
    40 mM 0.0425 mL 0.2123 mL 0.4247 mL 1.0617 mL
    50 mM 0.0340 mL 0.1699 mL 0.3398 mL 0.8494 mL
    60 mM 0.0283 mL 0.1416 mL 0.2831 mL 0.7078 mL

    * 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

    Help & FAQs
    • 如何产品改善基因沉默的效果？

      提高转染效率：首先可依据转染试剂说明书进行转染条件 (细胞密度，转染试剂用量，转染时间等)：优化 siRNA 浓度：siRNA 最佳工作浓度因不同的细胞类型及研究目的而异，这取决于 siRNA，细胞系和选择的分析方法。推荐 siRNA 工作浓度为 50 nM，也可以使用不同的浓度进行优化实验以达到最佳转染效率。但过高浓度的 siRNA 可能对细胞产生毒性。调整细胞的生长状态：细胞生长状态不好会影响转染效率。其次可尝试在其他细胞类型上进行转染。若由于实验模型限制无法使用其他细胞，可考虑更换转染试剂或转染方法 (如电转)。若优化之后提高转染效率（转染效率 80% 以上）还是无法改善敲低效果，则可以找我们重新免费设计 siRNA。

    • 同样的 siRNA 为什么在细胞 A 中有效，在细胞 B 效果不好？

      不同细胞可能转染效率不一样，基因表达水平也不一样，这些都与 siRNA 的作用效率有关。

    • 如果设置 FAM 阴性对照组是不是就可以不用做不带荧光的阴性对照呢？另外 GAPDH 的阳性对照只能通过 WB 和 qPCR 检测吗？可以通过流式检测其表达吗？

      我们三保一的套装中阴性对照有两个，一个是带 FAM 的，另一个是不带 FAM，带 FAM 的可以通过在荧光纤维镜下看是否转染进细胞了，建议都做。关于检测阳性对照，一般建议 qPCR 检测，因为我们的 siRNA 主要针对的是 mRNA，蛋白的检测周期的话会有差异，另外对比不同的靶标，转录本可能也会有差异，对蛋白的影响可能会有差异。

    • siRNA 产品怎么判断转染效率？

      可以通过检测转染了 FAM 标记阴性对照的细胞的荧光信号来确定转染效率。通过转染了 GAPDH 阳性对照的细胞确认转染实验中操作是否有问题。如果 GAPDH mRNA 表达降低，则证明转染实验中操作没有问题，GAPDH siRNA 正常发挥作用。如果 GAPDH mRNA 表达没有变化，则证明操作出现失误，转染失败。

    • 使用你们的 siRNA 为什么转染过程中细胞出现大量死亡？

      可能原因有：1）转染试剂浓度过高会产生细胞毒性。2）转染时的培养基中加入了抗生素，这会降低细胞转染的效率，甚至导致细胞死亡。3）转染之后细胞本身状态不佳。

    • 购买了你们的 siRNA，有推荐的转染试剂吗？

      MCE 推出最新转染试剂 HY-K2017 (siRNA/miRNA Transfection Reagent)，可用于高效率转染 siRNA。对于一些难转染的细胞如原代细胞、干细胞和 B 细胞系，也可以考虑选择电穿孔法。

    Keywords:

    Cilengitide188968-51-6EMD 121974西仑吉肽EMD121974EMD-121974IntegrinAutophagyApoptosisSTATPD-1/PD-L1PD-1/Programmed death-ligand 1integrinsανβ3ανβ5VitronectinInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Cilengitide
    目录号：
    HY-16141
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    我们的 Cookie 政策

    我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z